Infant Bacterial Therapeutics AB (publ)

OM:IBT B Stock Report

Market Cap: SEK 445.9m

Infant Bacterial Therapeutics Dividend

Dividend criteria checks 0/6

Infant Bacterial Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield2.3%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Earnings per share-SEK 10.56
Dividend yield forecastn/a

Recent dividend updates

No updates

Recent updates

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Aug 02
We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Infant Bacterial Therapeutics AB (publ)'s (STO:IBT B) CEO Compensation Is Looking A Bit Stretched At The Moment

May 02
Infant Bacterial Therapeutics AB (publ)'s (STO:IBT B) CEO Compensation Is Looking A Bit Stretched At The Moment

Infant Bacterial Therapeutics (STO:IBT B) Is In A Good Position To Deliver On Growth Plans

Apr 03
Infant Bacterial Therapeutics (STO:IBT B) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Situation

Sep 16
Here's Why We're Not Too Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Situation

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

May 11
We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate

Sep 23
We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate

We're Hopeful That Infant Bacterial Therapeutics (STO:IBT B) Will Use Its Cash Wisely

Apr 07
We're Hopeful That Infant Bacterial Therapeutics (STO:IBT B) Will Use Its Cash Wisely

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Dec 15
We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Aug 25
We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate

May 06
We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate

Anthon Jahreskog Just Bought A Sprinkling of Shares In Infant Bacterial Therapeutics AB (publ) (STO:IBT B)

Feb 07
Anthon Jahreskog Just Bought A Sprinkling of Shares In Infant Bacterial Therapeutics AB (publ) (STO:IBT B)

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if IBT B's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IBT B's dividend payments have been increasing.


Dividend Yield vs Market

Infant Bacterial Therapeutics Dividend Yield vs Market
How does IBT B dividend yield compare to the market?
SegmentDividend Yield
Company (IBT B)n/a
Market Bottom 25% (SE)1.5%
Market Top 25% (SE)4.4%
Industry Average (Pharmaceuticals)2.3%
Analyst forecast (IBT B) (up to 3 years)n/a

Notable Dividend: Unable to evaluate IBT B's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IBT B's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate IBT B's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as IBT B has not reported any payouts.


Discover strong dividend paying companies